Glossary > ICH Q10
ICH Q10 is an international guideline issued by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), which describes a comprehensive pharmaceutical quality system covering the entire product lifecycle—from pharmaceutical development through technology transfer and commercial production to product discontinuation. It forms the conceptual basis on which EU GMP and FDA cGMP were harmonized in terms of content.
Publisher: International Council for Harmonisation (ICH)
Current version: ICH Q10 (2008), with ongoing development under ICH Q13
The guideline is intended for pharmaceutical manufacturers and marketing authorization holders worldwide who wish to establish a systematic quality system that covers the entire product life cycle. It is recognized industry-wide as a framework and is incorporated into European, U.S., and other national regulatory frameworks, such as those in Japan and, increasingly, in emerging markets with their own regulatory authorities.
Process Performance and Product Quality Monitoring: Continuous Monitoring of Critical Quality Parameters
CAPA system: structured root cause analysis and corrective actions in the event of deviations
Change Management System: Formal evaluation and approval of all relevant changes
Management Review: Regular evaluation of system performance by top management
Knowledge management: systematic recording and sharing of process and product knowledge throughout the entire lifecycle
Continuous improvement: proactive refinement of processes rather than merely correcting errors
ICH Q10 is conceptually based on modern quality management principles, such as those underlying ISO 9001, but was developed specifically for the pharmaceutical industry. Beyond the general ISO 9001 requirements, ICH Q10 covers pharmaceutical-specific elements, such as structured knowledge management throughout the product lifecycle and close integration with regulatory GMP requirements. Therefore, ISO 9001 certification does not replace ICH Q10—conversely, however, a quality system structured according to ICH Q10 can be easily combined with an existing ISO 9001 structure.
Since ICH Q10 is not a standalone, legally binding regulation, there are no direct penalties. However, since key concepts have been adopted in EU GMP and FDA cGMP, gaps in the quality system—such as an inadequate CAPA or change management system—regularly lead to findings of nonconformity during GMP inspections, with the same consequences as direct GMP violations: notices of non-compliance, batch holds, and even the revocation of the manufacturing authorization.
Not directly, but key concepts have been incorporated into EU GMP and FDA cGMP and are therefore effectively mandatory.
ICH Q10 is specifically designed for the pharmaceutical industry and supplements general quality management principles with knowledge management and GMP integration.
Process performance monitoring, CAPA system, and change management system, all governed by management reviews.
Q8 governs development, Q9 governs risk management, and Q10 integrates both into a lifecycle-wide quality system.
The key component of a functioning pharmaceutical quality system in accordance with ICH Q10 is robust process performance monitoring: Without reliable, complete production data, it is impossible to operate an effective CAPA system or conduct a meaningful management review. Connected worker platforms such as weasl provide this data as an automatic byproduct of daily production, thereby laying the foundation for a quality system in accordance with ICH Q10.
Learn more about weasl and download our product flyer now.